It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SEE PDF] No specific patient or disease (age, sex, performance status, measurable residual disease level, white blood cell count, neutrophils and lymphocytes count, nervous system infiltration, previous allogenous stem cell transplantation, c-reactive protein level) characteristics were significantly associated with LTC occurrence. Life-threatening events occurred in 9% of B-ALL patients treated with blinatumomab in our cohort, necessitating ICU admission in 7% of the cases, which compares favorably with the rate observed after intensive chemotherapy (17.5%) [4] or CAR-T cells (32%) [5]. Availability of data and materials The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer